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Abstracts 
Cell-surface display of functional proteins is a powerful and useful tool for 
regulating and reinforcing cellular functions. In this study, I used a polyethylene glycol 
(PEG)-lipids consisting of a long PEG chain and a dioleylphosphatidylethanolamine 
(DOPE), named the biocompatible anchor for the membrane (BAM) to anchor arbitrary 
IgG onto the surface of apoptotic tumor cells (ATCs) to enhance the phagocytosis by 
dendritic cells (DCs) ex vivo, which may improve the efficacy of DC immunotherapy.  
The DC immunotherapy has become a promising strategy in adoptive cell therapy, 
particularly in cancer immunotherapy. These days, DCs loaded with ATCs coated with 
IgG were found to activate effective antitumor immunity. However, the employment of 
antigen-specific antibodies is expensive and therefore increases the medical cost. BAM-
modified molecules can bind to any type of cells without loss of their activities because 
the oleyl moieties can be inserted into the ubiquitous lipid bilayer membranes in a 
noncovalent manner. Therefore, I hypothesized that arbitrary IgG can be readily displayed 
on ATCs by conjugating with BAM, and that phagocytosis of ATCs into DCs can be 
enhanced through the interaction between the IgG displayed on the surface of the ATCs 
and the Fc receptor expressed on DCs. 
First, I attached BAM to IgG via amine coupling reaction. This simple method was 
successfully applied to four types of mammalian cells. Furthermore, treatment of ATCs 
with the IgG-BAM conjugate increased the phagocytosis ratio of ATCs by DCs, however, 
the effect was only about two-fold compared to no treatment. Since BAM are attached to 
the random lysine residue of IgG in this method, Fc-Fc receptor interaction might be 
disturbed by some BAM attached to Fc region. Therefore, I hypothesized that site-specific 
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lipidation of IgG is the best way to display IgG(Fc) on the cell surface without losing 
native activities between Fc and Fc receptor. 
Consequently, I developed a method for displaying Fc on the surface of ATCs 
through in situ enzymatic site-specific modification of BAM. Site-specific modification 
of proteins was performed via sortase A (SrtA)-mediated transpeptidation reactions. This 
enzyme recognizes substrates that contain an LPETG sequence and cleaves the amide 
bond between T and G, then react with the triglycine moiety of the peptides. I prepared 
LPETG-fused Fc domains of mouse IgG1 and IgG2a (Fc1-LPETG and Fc2a-LPETG) 
and GGGYC peptide conjugated BAM via thiol-maleimide chemistry. Fc1 and Fc2a were 
successfully attached to BAM displayed on ATCs through in situ SrtA-mediated 
modification. In addition, the phagocytosis rate of ATCs by DCs was increased almost 
four-fold by displaying Fc2a on the surface of ATCs. Furthermore, vaccination of the DCs 
which phagocytized Fc2a-BAM treated ATCs induced stronger tumor immunity and 
delayed tumor development in mouse. On the other hand, display of Fc1-LPETG showed 
only a slight increase in the phagocytosis rate. The difference in the phagocytosis rates 
between Fc1 and Fc2a is assumed to be derived from the property that IgG2a induce more 
active immune effector responses than IgG1 by interacting with Fc receptor, which 
indicates that site-specifically lipidated Fc maintained natural reactivity between Fc 
receptor. 
According to this study, the enzymatic method for displaying Fc on ATCs was 
successfully shown to induce strong Fc-Fc receptor interaction for effective DC 
immunotherapy. In addition, this method is applicable to broad cancer because this 
method could opsonize ATC with arbitrary IgG, without employing the tumor-specific 
IgG, which is difficult to obtain for any tumor cells and is expensive. Thus, the combined 
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use of a BAM and SrtA enzyme represents a very effective and simple approach to display 
target proteins on cells via exogenous incorporation onto cell membranes. This approach 
will not only lead to objective clinical responses in DC vaccines, but also become a 
promising tool for regulating and reinforcing cell-cell interactions in cell and tissue 
engineering fields. 
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1.1 Cell-surface protein modification 
Membrane proteins are key components of biological recognition systems used in 
cell-cell or cell-extracellular matrix interactions. Hence, cell surface modifications with 
functional proteins represent a powerful and useful tool for regulating and reinforcing 
cellular functions in cell engineering and cell therapy [ 1 ]. Compared with protein 
expression through gene transfer, direct protein transduction from the extracellular 
medium is more rapid, easily controllable in a concentration-dependent manner, and 
reliable because it does not require unpredictable processes such as transformation, 
folding and intercellular trafficking [2]. In particular, the incorporation of proteins into 
the cell membrane does not involve the troublesome transduction across the cellular 
membrane. Thus, many approaches for protein transduction onto cellular membranes 
have been studied. The reported methods can be classified broadly into two categories: 
modification of cell membranes [3, 4] and protein lipidation [5, 6]. In the former case, 
chemical and metabolic modification of membrane biomolecules is potentially toxic and 
may perturb cell physiology [7]. Therefore, recently, transduction of artificially lipidated 
proteins through noncovalent insertion of the lipid into the cell membrane has been 
reported as an attractive alternative approach. In particular, site-specific lipidation of the 
protein is the best way to display target proteins on the cell surface without losing native 
activities.  
Polyethylene glycol (PEG)-lipids consisting of a long PEG chain and a 
dioleylphosphatidylethanolamine (DOPE) were previously reported by Kato et al. as a 
biocompatible anchor for biomembranes (abbreviated to BAM) (Figure 1-1) [5]. BAM-
modified molecules can bind to any type of cell because the oleyl moieties can be inserted 
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into the ubiquitous lipid bilayer membranes in a noncovalent manner [5]. By attaching to 
BAM, various biomolecules such as biotin [5], an antagonistic peptide [8 ] and green 
fluorescent protein [5] were spontaneously displayed on living cells without loss of their 
activities. Other groups have also modified cell surfaces with functional biomolecules 
using PEG-lipids [1, 9, 10].  
 
1.2 Dendritic cell immunotherapy for cancer treatment 
The dendritic cell (DC) immunotherapy (Figure 1-2) has become a promising 
strategy in adoptive cell therapy, particularly in cancer immunotherapy [11, 12]. For DC 
vaccines against cancer, DCs are loaded with tumor antigens ex vivo, and upon 
administration into patients, the DCs with presenting antigenic epitopes can activate anti-
tumor effector T and B lymphocytes, and are capable of promoting natural killer (NK) T 
cells or NK cell activation [13]. Subsequently, these activated mediator and effector cells 
are reported to reject tumors in numerous studies using animal models [14, 15]. However, 
although a large number of patients had received DC vaccines in clinical trials, only a 
limited number of objective clinical responses have been reported [11, 14, 15]. This 
disappointing result has prompted further studies examining each step in DC vaccination, 
such as source and ex vivo manipulation of DCs, antigen-loading of DCs, timing and 
dosing of DC administration and the route of DC administration. In particular, the 
antigen-loading of DCs is critical because the choice of antigen influences the specificity 
of the immune response, and the choice of adjuvant defines the quality and magnitude of 
the anti-tumor response [14, 16]. 
The ideal tumor antigen for a DC vaccine should induce a broad repertoire of anti-
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tumor immunocytes with high avidity for tumor cells. However, in current trials, single 
MHC-class-I-restricted synthetic peptides are the most commonly used therapeutic 
antigens. The use of such single synthetic peptides is restrictive because it provides a 
limited repertoire, such as the possible occurrence of promoting tumor antigen escape 
variants and the limited activation of cytotoxic T-lymphocytes (CTL) [11, 17 ]. In 
addition, synthetic peptides-based DC vaccinations require prior knowledge of the 
sequence of the suitable-antigenic epitopes [16]. Conversely, over a decade ago, whole 
apoptotic tumor cells (ATCs) were found to represent promising antigen sources, because 
ATCs contain a broad spectrum of known and unknown antigens [16, 18, 19]. The use 
of ATCs potentially overcomes the limitations of synthetic peptides-based DC 
vaccinations. Such an approach has been presented, in which, DCs loaded with ATCs 
could induce activation of CTLs and helper T cells, as well as NK and γδ T cells [16]. 
Previous reports have suggested that activation of NK cells by DCs may be required for 
antitumor immunity in MHC-class-I-negative malignant tumors [20], and under certain 
conditions for successful CTL activation [21 ]. Thus, ATCs may provide a useful and 
effective source of antigens for overcoming the current problems associated with DC 
vaccine strategies. 
  Antigen-immunoglobulin G (IgG) complexes can efficiently sensitize immature 
DCs for activation of both CTLs and helper T cells in DC vaccine-based antitumor 
immunity [22, 23]. IgG-complexed antigens are internalized into DCs through the uptake 
mediated by receptors for the Fc domain of IgG (FcγR), and then, the antigenic peptides 
derived from the antigens are presented on MHC class I as well as MHC class II cells. In 
addition, the use of IgG can promote antigen presentation 100-fold more efficiently over 
pinocytosis of soluble antigens and effectively induce DC maturation [22]. These 
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advantages of antigen-IgG complexes were confirmed in a ATCs-based DC vaccination. 
Akiyama et al. reported that the ATCs bearing IgG, which were prepared by chemically 
modifying cell membranes with IgG, provided a more efficient vaccination against 
tumors [17]. However, chemical modification of the membrane of ATCs may alter the 
properties of antigens derived from tumor membrane proteins. Instead of chemical 
modification of IgG, tumor-specific antibodies can be attached onto the surface of tumor 
cells via their molecular recognition. Still, the employment of antigen-specific antibodies 
is expensive and therefore increases the medical cost [23, 24]. Consequently, alternative 
methods of displaying IgG on the ATC surface is likely to be required for the development 
of inexpensive and effective DC vaccines. 
In this study, to prepare an ATC-IgG complex using a simple and inexpensive 
approach, I used BAM for anchoring IgG onto the surface of ATCs. I hypothesized that 
arbitrary IgGs can be readily displayed on ATCs by conjugating with BAM, and that 
phagocytosis of ATCs by DCs can be enhanced through the interaction between the IgG 
displayed on the surface of the ATCs and the FcγR expressed on DCs. 
 
1.3 Objective of this study 
In this study, I developed a simple and inexpensive method for attaching IgG on the 
cell surface to enhance phagocytosis of ATCs by DCs ex vivo. To anchor arbitrary IgG 
on the surface of ATCs, I used BAM. In chapter 2, I developed random IgG-BAM 
conjugate which was successfully modified on to various types of cancer cells. Treatment 
of ATCs with the random IgG-BAM conjugate increased the phagocytosis ratio of ATCs 
by DCs two-fold when compared to no treatment. Although this phagocytosis-enhancing 
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effect was nearly identical to treatment with a tumor-specific IgG, the effect was still 
limited. To improve the effect of IgG-BAM conjugate, in chapter 3, I developed site-
specific IgG(Fc)-BAM conjugate by applying SrtA-mediated in situ enzymatic reaction. 
The phagocytosis rate of ATCs by DCs was increased almost four-fold by displaying site-
specific IgG(Fc)-BAM conjugate. Furthermore, vaccination of the DCs which 
phagocytized site-specific IgG(Fc)-BAM treated ATCs induced stronger tumor immunity 
and delayed tumor development in mouse. Finally, in general discussion, I describe the 
possibility of combination use of SrtA and BAM as a useful tool for regulating and 
reinforcing cell-cell interactions in cell and tissue engineering fields.
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Figure 1-1.  Chemical structure of biocompatible anchor for cell membrane (BAM). 
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Figure 1-2.  The outline of general dendritic cell immunotherapy for cancer treatment. 
 
 
 
Chapter 2. Studies on random IgG-BAM 
conjugate and enhancement of dendritic cell 
phagocytosis of apoptotic cancer cells 
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2.1 Introduction 
In this study, to develop a simple and inexpensive method for attaching IgG on the 
cell surface to enhance phagocytosis of ATCs by DCs ex vivo, I used BAM for anchoring 
IgG onto the surface of ATCs. BAM-modified IgG can bind to any type of cancer cell 
because the oleyl moieties can be inserted into the ubiquitous lipid bilayer membranes. 
Therefore, arbitrary IgGs can be readily displayed on ATCs by conjugating with BAM, 
and that phagocytosis of ATCs into DCs can be enhanced. In this chapter, I used BAM 
with NHS ester reaction group to conjugate with amine group of IgG (Figure 2-1). Initially, 
I optimized the conditions of amine coupling reaction between IgG and BAM. The IgG-
BAM conjugates prepared under various conditions were tested for their incorporation 
into cancer cells, and the incorporation rate was investigated using flow cytometry. Then 
I examined if the IgG-BAM treatment could enhance phagocytosis of ATCs by co-
culturing with DCs. 
 
2.2 Materials and methods 
2.2.1 Chemicals, antibodies and cell-lines 
All chemicals were commercially available and used as supplied without further 
purification. Purified mouse IgG2a was purchased from Beckman Coulter (CA, USA). 
Anti-human tumor cell specific antibody (SF-25) was purified from hybridoma-induced 
mouse ascites by protein A-Sepharose chromatography. For immunostaining of DC, 
phycoerythrin (PE)-conjugated mouse anti-CD11c antibody (Bioscience, CA, USA) was 
used. Cy3 or Cy5-labeled anti-mouse Fc antibody (Jackson ImmunoResearch laboratories, 
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PA, USA) was used for staining Fc. Cell lines, HeLa and Ba/F3 were purchased from 
ATCC (VA, USA). HepG2, B16 and the hybridoma secreting SF-25 were kindly provided 
by Tella, Inc (Tokyo, Japan). These cells were cultured in RPMI1640 or DMEM (Nissui, 
Tokyo, Japan) supplemented with 10% FBS, 2.05 mM l-glutamine, 30 μg/mL kanamycin 
and 0.2% NaHCO3. 
 
2.2.2 Synthesis of BAM 
BAM was synthesized by coupling dioleylphosphatidylethanolamine (DOPE, 
COATSOME ME-8181 from NOF Corporation, Tokyo, Japan) and PEG 
disuccinimidylglutarate (SUNBRIGHT DE-050GS from NOF Corporation). DOPE (17.6 
mg, 28.8 μmol) and PEG disuccinimidylglutarate (151 mg, 30.2 μmol) were dissolved 
into 10 mL of anhydrous dichloromethane. Distilled triethylamine (60 μL, 431 μmol) was 
added, and the mixture was left to stir at room temperature for 1 h. After checking the 
consumption of DOPE on a thin layer chromatography, the crude product was precipitated 
by adding into 200 mL of diethyl ether, followed with centrifugation. The supernatant 
was removed by decantation. Vacuum drying the precipitation yielded white solid (132 
mg, 84%). 
 
2.2.3 Preparation of BAM-conjugated IgG 
BAM-conjugated IgG (IgG-BAM) was prepared by reacting mouse IgG and BAM 
in borate buffer (100 mM, pH 8.3) including 2.5% DMSO. The final concentration of IgG 
was 1 mg/mL (6.67 μM), and that of BAM was varied from 6.60 to 330 μM. The reaction 
mixture was incubated for 1 h at room temperature and the reaction was quenched by 
adding Tris-HCl buffer (pH 8.0) to give a final concentration of 50 mM. The product 
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solution was purified by dialysis against PBS to remove unconjugated BAM, DMSO and 
a by-product. The purified products were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and matrix-assisted laser 
desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) with 
Autoflex Speed (Bruker Daltonics, Leipzig, Germany). 
 
2.2.4 Incorporation of IgG-BAM conjugates onto cell membrane 
The cancer cells (1 × 106 cells) were incubated in 100 μL of IgG-BAM solutions (1 
μM in PBS) at room temperature for 15 min. As control experiments, cells were treated 
with IgG, BAM, or SF-25 solutions under the same condition, respectively. After 
treatment, the cells were washed twice with PBS. To evaluate the incorporation of IgG 
into the cell membrane, the IgG on the cell surfaces were fluorescently stained by Cy3-
labeled anti-mouse Fc antibody according to standard protocols, and red-fluorescent cells 
were analyzed as Fc-positive cells by flow cytometry with a flow cytometer FACS 
Calibur using the CellQuest software (BD Labware, CA, USA). Additionally, the stained 
cells were observed with a confocal laser scanning microscope (CLSM) (TCS-NT, Leica 
Microsystems, Bensheim, Germany). 
 
2.2.5 Generation of bone marrow-derived DCs 
Bone marrow cells were obtained from female C57BL/6 mice (10 wk old, from 
Charles River Breeding Laboratories, Tokyo, Japan) in accordance with a protocol 
approved by the Animal Care and Use Committee of the University of Tokyo. After red 
cells were lysed with ACK lysing buffer (Lonza, NJ, USA), bone marrow cells were 
cultured at 1 × 106 cells/mL in RPMI medium (HyClone, UT, USA) in the presence of 20 
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ng/mL murine recombinant GM-CSF (rGM-CSF, Peprotech, UK). The cultures were fed 
by replacing 75% of the medium with a fresh rGM-CSF-containing medium on day 1 and 
4. Non-adherent cells and weakly adherent cells on day 6 of culture were harvested by 
strong pipetting and used as DCs in the following experiments. 
 
2.2.6 Phagocytosis of apoptotic HeLa cells by DCs 
HeLa cells were fluorescently stained with 5- or 6-(N-Succinimidyloxycarbonyl)- 
fluorescein 3',6'-diacetate (CFSE; Dojindo, Kumamoto, Japan) for 5 min. These stained 
HeLa cells were irradiated with ultra-violet (UV) light for 5 min and incubated for 6 h to 
induce apoptosis. Then, to incorporate IgG into the cell membrane, apoptotic HeLa cells 
were treated with IgG-BAM as described above. As control experiments, apoptotic HeLa 
cells were also treated with BAM and SF-25. After treatment, apoptotic HeLa cells (2 × 
105 cells) were co-cultured with DCs (1 × 106 cells) in 500 μL of RPMI medium. After 
co-culturing for 3 h, all cells were treated with a PE-conjugated anti-CD11c antibody for 
fluorescently-staining DCs. The cells were observed with CLSM and quantitatively 
analyzed using FACS, as described above. The cells possessing both green and red 
fluorescence were identified as the DC phagocytizing apoptotic HeLa cells [25 ]. The 
phagocytosis rate of the DCs was determined by calculating the ratio of the double 
fluorescent-positive cells to the total red fluorescent-positive cells. 
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2.3 Results and discussion 
2.3.1  Optimization of random IgG-BAM conjugation 
The process of conjugating IgG and BAM was optimized by changing the final molar 
ratio of BAM to IgG. The BAM molecule has an amine-reactive group at the end of the 
PEG chain and opposite to the lipid moiety, and reacts with lysine residues on IgG. Such 
random amine-coupling reactions onto IgG had been extensively used as a standard 
modification method because of their simplicity [26 ,27 ]. In the context of medical 
applications of PEGylated IgGs, the effects of random PEGylation on the effector 
function of IgG have been studied. Many studies using IgG modified with PEG of several 
kDa showed that FcγR binding to IgG was inhibited at high conjugation ratios of PEGs 
per IgG [26]. Therefore, to minimize the inhibition of FcγR binding by attachment of 
BAM, the condition of IgG-BAM conjugation was optimized by searching for a suitable 
conjugation ratio of BAM per IgG. The degree of attachment of BAM to IgG was 
qualitatively analyzed by SDS-PAGE (Figure 2-2A). As the molar ratio of BAM to IgG 
increased, the two bands derived from the heavy and light chains of IgG shifted to higher-
molecular-weight species and broadened (Figure 2-2A, lanes 5~7), and finally, at the 
IgG:BAM ratio of 1:50, the bands of IgG disappeared and barely migrated onto the SDS-
PAGE (Figure 2-2A, lane 8). In a previous report, a similar shift and broadening was 
observed in the band patterns of IgG modified with 5-kDa PEGs, and these changes were 
shown to correspond to the degree of PEG attachment [28]. Furthermore, MALDI-TOF 
MS analysis showed that IgG-BAM conjugation at the IgG:BAM ratio of 1:5 yielded 
IgGs with zero, one and two PEGs per IgG (Figure 2-2B). At that of 1:20, a broaden peak 
was observed around the molecular weight of IgG with from one to five PEGs per IgG in 
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the MS spectrum (Figure 2-2B, bottom). Thus, the present result indicates that IgGs 
bearing various amounts of BAM were successfully prepared by changing the molar ratio 
of BAM to IgG from 1 to 50. 
 
2.3.2  Incorporation of IgG-BAM conjugates onto the cell membrane 
Incorporation of IgG-BAM conjugates onto the membrane of cancer cells was 
confirmed by flow cytometer analysis. HeLa cells treated with IgG-BAM conjugates were 
stained with a fluorescent-labeled anti-mouse Fc antibody, and then, the ratio of Fc-
positive cells was determined by flow cytometry. Compared with the control cells (treated 
with only IgG), the Fc-positive ratios of the cells treated with IgG-BAM conjugates 
effectively increased (Figure 2-3A). In particular, treatment with the IgG-BAM 
conjugated at the IgG:BAM ratio of 1:20 gave the largest Fc-positive ratio, up to ~90%. 
Similarly, CLSM observations clearly indicated that IgG-BAM conjugates at high 
conjugation ratios of BAM could effectively incorporate into the cell membrane (Figure 
2-3B).  
On the other hand, although the IgG-BAM conjugated at the IgG:BAM ratio of 1:50 
should bear the largest amount of BAM, the Fc-positive ratio was inclined to be smaller 
than that conjugated at the IgG: BAM ratio of 1:20 (p < 0.08). This is probably because 
the binding of fluorescent-labeled anti-Fc antibody to IgG was inhibited with the 
conjugated BAM at high conjugation ratios of BAM per IgG. As described above, in the 
case of random PEGylation of IgG, similar inhibition was found to be dependent on the 
conjugation ratio [26]. In addition, when the BAM modified near the Fc domain of 
antibody was inserted into the cell membrane, the fluorescent-labeled anti-Fc antibody 
would be unable to approach the Fc domain because the Fc domain was buried in cell 
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membrane. The use of high conjugation ratios of BAM per IgG may increase the chance 
of modification near the Fc domain with BAM, thereby blocking the interaction with the 
anti-Fc antibody. From these results, I performed further experiments using the IgG-BAM 
conjugate prepared at the IgG:BAM ratio of 1:20. 
To demonstrate the versatility of the present method, a large variety of cell lines 
including HepG2, Ba/F3 and B16 were treated with the IgG-BAM conjugate. I selected 
HepG2 as a second human adenocarcinoma, Ba/F3 as a non-adherent cell and B16 as a 
murine cancer cell. Figure 2-4 shows that the Fc-positive ratios of all treated cell lines 
were almost 100%, whereas those of the cells treated with intact IgG were <30%. From 
this result, the IgG-BAM conjugate was successfully incorporated into the cell membrane 
through the interaction between BAM and the cell membrane, regardless of the cellular 
characteristics such as cellular derivation and adhesion properties. This is because the 
dioleyl moiety of BAM interacts with the ubiquitous lipid bilayer of cells.  
The efficiency of the presentation of Fc on the cell surface was almost the same 
between IgG-BAM and the tumor-specific monoclonal antibody SF-25 (Figure 2-4). SF-
25 was reported to bind a wide range of human cancer cell lines [29]. As such, the use of 
specific IgG against a ubiquitous antigen on cancer cells may be applied in the preparation 
of ATC-IgG complexes and be effective against a wide range of tumors. However, such 
antigen-specific monoclonal IgGs have limited medical applications. Particularly, 
antigen-specific monoclonal IgGs are obtained from animals including mouse, rabbit and 
goat. Therefore, the humanization of the IgG is required to avoid immune activation in 
patients and for enhancing effector cell activation [30 ]. In contrast, using the present 
BAM-conjugation method, arbitrary human IgGs obtained from blood can be employed. 
Thus, IgG-BAM is a promising tool for supplying safe ATC-IgG complexes at a low cost. 
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2.3.3  Effects of incorporated IgG-BAM on phagocytosis by DCs 
To evaluate whether treatment of IgG-BAM can enhance the uptake of ATCs by DC, 
the rate of phagocytosis was analyzed after co-culturing the treated ATCs with immature 
DCs. The ATCs and DCs were stained with a green fluorogenic reagent, CFSE, and a red 
fluorescent protein-conjugated anti-CD11c antibody, respectively. After co-culturing, the 
cells possessing both green and red fluorescence were identified as the DCs that had 
phagocytized ATCs [25], and such double-positive cells were observed with CLSM and 
quantitatively analyzed using flow cytometry (Figure 2-5). Figure 2-5A shows the CLSM 
image of the DCs cocultured with the ATCs treated with IgG-BAM. In the red-fluorescent 
image, the outer membrane of the DCs was stained red due to the attachment of the PE-
conjugated anti-CD11c antibody. In contrast, in the green image, the whole ATCs 
fluoresced green. In the merged image, several red-stained cells were observed to have 
incorporated green-stained bodies. Consequently, the florescent images clearly confirm 
that DCs have phagocytized ATCs. 
Figure 2-5B shows the phagocytosis rate of DCs under various conditions of 
treatment for ATCs. Compared with no treatment, treatment with IgG-BAM increased the 
phagocytosis rate more than two-fold. For over forty years, PEG has been commonly used 
as an effective fusogenic reagent for somatic cells [31 ]. As a control experiment, I 
investigated the effect of treatment with only BAM on the uptake of ATCs. Treatment 
with only BAM slightly increased the phagocytosis rate (Figure 2-5B). These results 
strongly suggest that the enhancement effect of IgG-BAM is not derived from the 
fusogenic properties of the PEG moiety but from the effective presentation of IgG on the 
ATC surface. In a previous report on ATC chemically-modified IgG, the phagocytosis rate 
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was enhanced almost two-fold by IgG modification [17]. Thus, the present enhancement 
of DC phagocytosis by IgG-BAM treatment is essentially the same as that observed when 
IgG is chemical modified. However, in contrast to chemical modification approaches, the 
present IgG-BAM treatment has the distinct advantage of enhancing phagocytosis 
without altering any chemical structures on the cell-surface antigens. There are many 
well-known cell surface antigens present on tumor cells, such as MUC-1 and CCA-1. 
Alteration in the chemical properties of such cell surface antigens may lead to decreases 
in the repertoire of antigenic epitopes for presentation to anti-tumor effector and mediator 
cells. On the other hand, the rate of intracellular processing of antigen remained virtually 
unaffected by the presence of IgG or PEGylated lipids on the antigen surface [32,33,34]. 
Thus, noncovalent treatment with IgG-BAM is a promising method for activating a broad 
repertoire of anti-tumor immunocytes.  
As shown in Figure 2-5 , the enhancement effect when using IgG-BAM was almost 
the same as observed for SF-25. Since IgG-BAM incorporates anywhere on the surface 
of the lipid bilayer of ATCs, the amount of presented IgG on ATCs is presumably limited 
only by the surface area of the ATC, whereas the binding amount of Ag-specific IgG, such 
as SF-25, is limited by the surface amount of Ag. Thus, treatment with IgG-BAM has the 
potential advantage of presenting a relatively large amount of IgG on the cell surface. 
Conversely, IgG-BAM potentially has a disadvantage in its immunological effector 
activities. As described above, random PEGylation of IgG has been reported to decrease 
the effector activities of IgG through interfering with FcγR binding [26,35]. Presumably, 
random BAM modification similarly interferes in the interaction between the Fc domain 
on ATCs and the FcγR on DCs. In the present study, treatment with IgG-BAM may exert 
an enhancing effect that was comparable with SF-25. This is probably because 
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optimization of the BAM-conjugation condition minimized the disadvantage of IgG-
BAM in the mean affinity with FcγR, and the advantage in the presentation amount 
countered this potential disadvantage. 
 
2.4 Conclusion 
In this chapter, I prepared IgG-BAM via random amine-coupling reaction. Random 
amine-coupling reaction is a standard modification method to attach molecules onto IgG, 
however, as shown in previous studies, random and high conjugation ratios of PEGs per 
IgG inhibit the effector function of IgG such as interaction between FcγR. Therefore, I 
tried to minimize the inhibition of Fc-FcγR interaction by searching for a suitable 
conjugation ratio of BAM per IgG. As a result, I concluded that the IgG:BAM ratio of 
1:20 is the optimal condition to prepare IgG-BAM conjugation via random amine-
coupling reaction. Next, cancer cells were treated with random IgG-BAM conjugate and 
the result indicated that by using random IgG-BAM conjugate, arbitrary IgG were 
successfully modified on cancer cell surfaces regardless of the cellular characteristics. 
Furthermore, ATCs treated with random IgG-BAM conjugates were more efficiently 
phagocytosed by DCs than untreated ATCs ex vivo. This result is consistent with a 
previous report on ATC chemically-modified IgG, which the phagocytosis rate was 
enhanced almost two-fold by IgG modification. In addition, this enhancement rate of 
treatment with IgG-BAM was essentially identical to the treatment rate with an Ag-
specific IgG. This result indicates that IgG-BAM treatment enhances the efficacy of ATC-
based DC vaccinations without the requirement of an expensive Ag-specific IgG. 
Theoretically, unlike Ag-specific IgG, since IgG-BAM incorporates anywhere on the 
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surface of the lipid bilayer of ATCs, the amount of IgG presented on ATCs is not limited 
by the surface amount of Ag. Thus, treatment of cancer cells with IgG-BAM conjugates 
has the potential advantage to induce stronger reaction between dendritic cells by 
displaying larger amount of Fc. However, the effect was only about two-fold compared 
to no treatment. Although I optimized the condition of amine-coupling reaction, still it is 
concerned that interaction between Fc and FcγR might be disturbed by some BAM 
attached to lysine residue of Fc regions, since lysine residues present in the structure were 
uniformly distributed on the Fab and Fc regions. Therefore, it is assumed that by 
investigating the reaction between IgG and BAM, ATCs might be phagocytosed by DCs 
more efficiently. To maximize the effect of IgG-BAM conjugate on DC immunotherapy, 
BAM must attach to IgG at the site which may not disturb the interaction between Fc and 
FcγR and this could be achieved by site-specific conjugation of IgG and BAM. 
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Figure 2-1.  (A) Chemical structure of BAM used in chapter 2. (B) Schematic diagram 
of the incorporation of BAM-conjugated IgG into the cell membrane. 
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Figure 2-2.  Optimization of the condition of IgG-BAM conjugation by changing the 
final molar ratio of BAM to IgG. (A) Qualitative analysis of the attachment of BAM to 
IgG by a reducing 7.5% polyacrylamide SDS-PAGE gel stained with Coomassie brilliant 
blue. Lane 1, protein molecular weight markers in kDa; lane 2, BAM as a control; lane 3, 
IgG as a control; lanes 4-9; IgG treated with BAM at various ratios: 1:1, 1:5, 1:10, 1:20, 
1:50 and 1:100. (B) MALDI-TOF MS spectra of intact IgG (top), IgG treated with BAM 
at the IgG:BAM ratio of 1:5 (middle) and 1:20 (bottom). 
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Figure 2-3.  Optimization of the condition of IgG-BAM conjugation by changing the 
final molar ratio of BAM to IgG. HeLa cells were treated with IgG-BAM conjugates 
prepared in various conditions and stained with PE-labeled anti-Fc antibody. (A) 
Qualitative analysis of the incorporation of IgG-BAM conjugates into the membrane of 
HeLa cells by flow cytometry (n = 3). (B) CLSM observation. Bar = 40 m. 
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Figure 2-4.  FACS analysis of Fc-positive ratios of various cell lines treated with IgG-
BAM conjugate. Fc domains of IgG were stained with fluorescent-labeled anti-Fc 
antibody. Each data point represents the mean ± S.E. (n = 3). 
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Figure 2-5.  Analysis of the effects of the incorporated IgG-BAM on phagocytosis by 
DCs. Apoptotic HeLa cells and DCs were stained with CFSE and PE respectively. 
Apoptotic HeLa cells were treated with BAM, IgG-BAM conjugates or SF-25 antibody, 
and then, co-cultured with DCs to induce phagocytosis. (A) CLSM image of the DCs co-
cultured with the apoptotic HeLa cells treated with IgG-BAM. Bar = 20 m. (B) The ratio 
of DC phagocytizing apoptotic HeLa cells analyzed by flow cytometry. (n = 3, * p < 0.05 
vs non-treated (student’s t-test)). 
 
 
Chapter 3. Studies on in situ enzymatic site-
specific Fc-BAM conjugate and application to 
dendritic cell therapy 
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3.1 Introduction 
Random IgG-BAM conjugate studied in previous chapter enhanced DC 
phagocytosis of apoptotic cancer cells. However, the effect was not enough, presumably 
because interaction between Fc and FcγR might be disturbed by some BAM attached to 
Fc region randomly. Therefore, in this chapter, I studied on site-specific IgG-BAM 
conjugation which may not disturb Fc-FcγR interaction to improve the efficacy of DC 
immunotherapy. 
For site-specific lipidation, chemical [36, 37] and chemoenzymatic strategies [38, 
39] are now available. For example, a model fluorescent protein was incorporated into 
the membrane of living cells through enzymatic site-specific lipidation [38]. However, 
conventional site-specific lipidation methods require the coexistence of amphiphilic 
reagents such as polar organic cosolvents and detergents that suppress aggregation of 
lipidated proteins in vitro [37-39]. Depending on the kind of protein and target cells, the 
usage of amphiphilic reagents may lead to protein denaturation or cytotoxicity.  
In this study, site-specific modification of proteins was performed via sortase A 
(SrtA, EC 3.4.22.70)-mediated transpeptidation reactions. Among the family of 
transpeptidases, the Staphylococcus aureus SrtA is the most extensively used enzyme for 
in vitro site-specific linkage of proteins with synthesized compounds in various 
applications [ 40 , 41 ]. This enzyme recognizes substrates that contain an LPXTG 
sequence, where X is a variable amino acid, and cleaves the amide bond between T and 
G, resulting in the formation of the thioester intermediate with the carboxyl group of T at 
the active-site cysteine. Successively, this thioester intermediate undergoes nucleophilic 
attack by an N-terminal amino group of the oligoglycine substrates, thereby producing 
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ligated products. Here, the peptide including the triglycine sequence at the N-terminus 
(GGGYC) was introduced onto the cell surfaces by conjugation with BAM. The GGGYC 
peptide was modified with BAM via thiol-maleimide chemistry (Figure 3-1A). 
Accordingly, Fc domains of IgG bearing a LPETG sequence at their C-terminus were 
prepared, and then reacted with the triglycine moiety of the peptides displayed on cancer 
cells through the SrtA-mediated transpeptidation (Figure 3-1B). 
 
3.2 Materials and methods 
3.2.1 Preparation of the GGGYC-BAM 
A maleimidyl PEG-lipid, consisting of DOPE, PEG of 90 units and maleimide 
(MAL-BAM) was a gift from NOF Corporation (Tokyo, Japan). A pentapeptide with the 
sequence Gly-Gly-Gly-Tyr-Cys (GGGYC) was synthesized by standard Fmoc solid-
phase peptide synthesis and purified by reversed-phase high-performance liquid 
chromatography (RP-HPLC). The GGGYC pentapeptide with a calculated mass of 454.2 
Da was identified by MALDI-TOF MS at mass-to-charge ratios (m/z) of 455.4 for [M + 
H]+ and 477.4 for [M + Na]+. The GGGYC peptide was modified with MAL-BAM 
through a thiol-maleimide Michael addition in a MOPS buffer (20 mM, pH 7.0) including 
5% DMSO. In the reaction mixture, the final concentrations of the GGGYC peptide and 
MAL-BAM were 1 and 5 mM, respectively. The reaction mixture was incubated 
overnight at room temperature. The reaction mixture was incubated for overnight at room 
temperature. The disappearance of free GGGYC peptide after incubation was confirmed 
by RP-HPLC analysis (Figure 3-2). The reactant was abbreviated as GGGYC-BAM. 
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3.2.2 Expression and purification of proteins 
PrimeSTAR Max DNA polymerase (Takara Bio Inc., Shiga, Japan) was used for 
PCR, and all PCR-amplified sequences were verified by DNA sequencing. Sortase A 
(SrtA) was expressed and purified by following previous report [42]. The enhanced green 
fluorescent protein (EGFP) bearing a Leu-Pro-Glu-Thr-Gly (LPETG) sequence and a 
hexahistidine tag at the C-terminus (EGFP-LPETG) was expressed and purified as follows. 
First, the expression plasmid for EGFP-LPETG was constructed as follows: The gene 
encoding EGFP-LPETG was obtained by PCR from pEGFP-N1 (Clontech Laboratories, Inc., 
CA) using the forward primer (5’-CGCGCGCCAT GGTGAGCAAG GGCGAGGAG-
3’) and the reverse primer (5’-CGCGCGGATC CCGACCAGTT TCAGGAAGCT 
TGTACAGCTC GTCCATGCCG-3’), and was subcloned into the NcoI/BamHI sites of 
pET-32b(+) (Novagen, Inc., Madison, WI, USA) to yield pET32b-EGFP-LPETG. This 
expression plasmid was then transformed into E. coli BL21 Star(DE3) pLysS cells. The 
cells were grown in LB medium to an OD (600 nm) value of 0.7 at which time expression 
of the protein was induced by the addition of isopropyl--D-thiogalactopyranoside 
(IPTG) to a final concentration of 1.0 mM. After growth for an additional 16 h at 27°C, 
the cells were harvested by centrifugation. The cell pellets were resuspended in 50 mM 
Tris-HCl pH 7.5, 150 mM NaCl and lysed by sonication. EGFP-LPETG was purified from 
the soluble fraction of the lysate using Ni-NTA columns (HisTrap FF crude column; GE 
Healthcare, Waukesha, WI, USA) equilibrated with 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl and 20 mM imidazole. EGFP-LPETG was eluted from the column with a linear 
gradient of imidazole (20-500 mM). The fractions containing EGFP-LPETG were collected 
and concentrated by ultrafiltration using Amicon Ultra-50 filter units (50 kDa molecular 
weight cut-off (MWCO); Millipore, Billerica, MA, USA). The concentrated protein was 
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subjected to anion exchange chromatography on a Hi-Trap Q FF crude column (GE 
Healthcare). The protein was eluted with a linear gradient of NaCl (150-500 mM). The 
fractions containing the protein were collected, and the thioredoxin tag derived from the 
pET32b vector was removed using enterokinase (EK Max; Invitrogen, Carlsbad, CA, 
USA). Ten units of EK Max were added to the fractions containing the protein and 
incubated at 4°C for 16 h, and the mixture was concentrated by ultrafiltration using an 
Amicon Ultra-30 filter unit (30 kDa MWCO; Millipore). The concentrated protein was 
subjected to gel-filtration chromatography on a Hi-Load Superdex 16/60 pg column (GE 
Healthcare), pre-equilibrated with 50 mM Tris-HCl pH 7.5 and 150 mM NaCl. The 
purified EGFP-LPETG-His6 was concentrated with an Amicon Ultra-30 filter unit.  
Expression vectors for the Fc domains of mouse IgG1 and IgG2a bearing a LPETG 
sequence and a hexahistidine tag at the C-terminus (Fc1-LPETG and Fc2a-LPETG) were 
constructed as follows. The gene encoding Fc1-LPETG was obtained by PCR from cDNA 
extracted from SF25 (a mouse IgG1 monoclonal antibody) expressing hybridomas using 
the forward primer (5′-GCCCTGCAGA GTGCCCAGGG ATTGTGG-3′) and the reverse 
primer (5′-CCGGCGGCCG CTCAATGGTG GTGATGGTGA TGTCCTCCGG 
TTTCAGGCAA TTTACCAGGA GAGTGGGAGA G-3′), and was subcloned into the 
PstI/NotI sites of pDisplay (Life Technologies, Gaithersburg, MD, USA) to yield 
pDisp/Fc1-LPETG. The Fc1 ORF was identical to the GenBank accession no. FJ232993. 
The gene encoding Fc2a-LPETG was obtained by PCR from a synthesized DNA coding 
Fc2a (GenScript USA Inc., Piscataway, NJ, USA) using the forward primer (5′-
GCCGCTGCAG ACCACGCGGC CCC-3′) and the reverse primer (5′-CCGGCGGCCG 
CTCAATGGTG GTGATGGTGA TGTCCTCCAG TTTCAGGCAA CTTCCCTGGT 
GTGCGAC-3′), and was subcloned into the PstI/ NotI sites of pDisplay to yield 
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pDisp/Fc2a-LPETG. The Fc2a ORF was identical to the GenBank accession no. V00798. 
These expression vectors were transfected into Chinese hamster ovary (CHO) cells using 
the Lipofectamine™ LTX Reagent, with the PLUS™ Reagent (Life Technologies). Two 
days after transfection, the stable CHO clones producing Fc1-LPETG or Fc2a-LPETG were 
selected in G418 medium (1.2 mg/mL) for two weeks. Approximately 100 mL of culture 
medium was collected from each stable CHO culture dish. From the collected media, Fc1-
LPETG and Fc2a-LPETG were purified using Ni-NTA columns (HisTrap FF crude column), 
equilibrated with 20 mM NaPi, 5 mM imidazole, pH 7.4. Fc1-LPETG and Fc2a-LPETG were 
eluted from the column with elution buffer (20 mM NaPi, 500 mM imidazole, pH 7.4), 
and the relevant fractions were dialyzed against PBS. 
 
3.2.3 SrtA-mediated reaction in solution 
50 μM of GGGYC-BAM was dissolved in a reaction solution, 50 μM EGFP-LPETG 
and 6 μM SrtA in the SrtA reaction buffer (50 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 
8.0). After incubation for 2 h at room temperature, this reaction mix solution was 
employed for SDS-PAGE analysis. 
 
3.2.4 SrtA-mediated reaction on living cells 
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Nissui, 
Tokyo, Japan) supplemented with 10% FBS, 2.05 mM L-glutamine, 30 μg/mL kanamycin 
and 0.2% NaHCO3. Initially, the culture medium was removed from the dishes and HeLa 
cells were rinsed with PBS. The cells were then incubated in a GGGYC-BAM solution 
(50 μM, in PBS) at room temperature. After incubation for 15 min, cells were rinsed twice 
with PBS to remove any free GGGYC-BAM. Next, cells were incubated in a reaction 
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solution, 50 μM EGFP-LPETG and 6 μM SrtA in a SrtA reaction buffer (50 mM Tris, 150 
mM NaCl, 5 mM CaCl2, pH 8.0). After incubation for 2 h at room temperature, cells were 
rinsed twice with PBS to remove SrtA and free EGFP-LPETG. As control experiments, 
without GGGYC-BAM treatment, intact cells were incubated in a reaction solution under 
the same condition, or cells treated with the GGGYC-BAM were incubated in a solution 
including only EGFP-LPETG or only SrtA. To evaluate the display of EGFP on cell 
membranes, the treated cells were observed with CLSM (LSM510; Carl Zeiss Co., Ltd, 
Germany) equipped with an Argon laser (488 nm). 
For flow cytometry and SDS-PAGE analysis, cells must be transferred from culture 
dishes to plastic tubes. To avoid digestion of the displayed EGFP during the collection 
process, the cells were harvested before treatment with the GGGYC-BAM in the protocol 
described above. First, cultured HeLa cells were treated with 0.25% Trypsin-EDTA (Life 
Technologies) for 3 min at 37°C. Then, 1 × 106 collected cells were placed into a plastic 
tube and suspended into the GGGYC-BAM solution (50 μM). This was followed by 
incubation for 15 min. The treated cells were washed twice with PBS using centrifugation 
to harvest the cells. Next, cells were re-suspended into the reaction solution including 
SrtA and EGFP-LPETG, and incubated for 2 h, followed by two washing steps with PBS. 
Other detailed conditions were the same as described above. To quantitatively evaluate 
the display of EGFP on cell membranes, green-fluorescent-positive cells were analyzed 
as EGFP-positive cells by flow cytometry with a flow cytometer FACS Calibur using the 
CellQuest software (BD Labware, Franklin Lakes, NJ, USA).  
 
 
 
33 
 
3.2.5  SDS-PAGE and western blotting analysis 
The reaction mixtures described in Section 3.2.3 and the lysates of the treated cells 
in Section 3.2.4 were fractionated by 12% SDS-PAGE. The SDS-PAGE gel was scanned 
with a Typhoon 9400 Scanner (GE Healthcare) using the excitation laser at 488 nm for 
EGFP-fluorescent imaging. For western blotting analysis, the fractionated proteins were 
electrotransferred from the SDS-PAGE gel onto a PVDF membrane. The blots were 
incubated with HRP-labeled anti-hexahistidine antibody (R&D Systems, Minneapolis, 
MN, USA) and stained using Chemi-Lumi One (Nacalai Tesque, Kyoto, Japan). 
 
3.2.6 SrtA-mediated in situ reaction of Fc-LPETG and GGGYC-BAM on E.G7 cells 
A murine thymoma cell line, E.G7 (EL-4 cells transfected with the chicken OVA 
cDNA) was kindly gifted by Prof. Tadatsugu Taniguchi at The University of Tokyo. E.G7 
cells were cultured in RPMI1640 medium (Nissui, Tokyo, Japan) supplemented with 10% 
FBS, 2.05 mM L-glutamine, 30 μg/mL kanamycin and 0.2% NaHCO3. E.G7 cells were 
irradiated with UV light for 5 min and incubated for 6 h to induce apoptosis. These non-
adherent E.G7 cells were treated with the GGGYC-BAM as described in Section 3.2.4. 
The treated cells were then re-suspended into the reaction solution including 6 μM SrtA 
and 50 μM Fc-LPETG (Fc1-LPETG or Fc2a-LPETG), and incubated for 2 h, followed by two 
washes with PBS. Other detailed conditions were the same as described in Section 3.2.4. 
 
3.2.7 Phagocytosis of apoptotic E.G7 cells by DCs 
The Fc-BAM treated apoptotic E.G7 cells were prepared as described in Section 
3.2.6. Apoptotic E.G7 cells (2 × 105 cells) were co-cultured with mouse bone marrow 
derived DCs (1 × 106 cells) in 500 μL of RPMI medium for 3 h at 37°C. When the co-
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cultured cells were analyzed with a flow cytometer, apoptotic E.G7 cells were 
fluorescently stained with CFSE (Dojindo, Kumamoto, Japan) for 5 min before Fc-
display treatment. After co-culturing, all cells were treated with a PE-conjugated anti-
CD11c antibody for fluorescently-staining DCs. The cells were analyzed using FACS, as 
described in Section 2.2.6. 
 
3.2.8 Tumor-bearing mouse model 
DCs for vaccination were prepared by co-culturing with apoptotic E.G7 cells as 
described above (Section 3.2.7). C57BL/6 6 wk old female mice were immunized 
intraperitoneally with prepared DCs (1 × 106 cells in 100 μL PBS) on day 1 and day 7. At 
day 14, these mice were confronted subcutaneously with 5 × 104 E.G7 cells. Tumor sizes 
were measured every day after tumor injection. Tumor volume (V (mm3)) was calculated 
using the formula: V = 0.5 x L x W2, where L is the longest diameter and W is the shortest 
diameter in mm. Mice were ethically sacrificed when the tumor volume exceeded 2,000 
mm3.  
 
3.2.9 In vivo cytotoxicity assay 
C57BL/6 6 week old female mice were immunized with prepared DCs on day 1 and 
day 7 as described above (Section 3.2.8). E.G7 cells were fluorescently stained with CFSE 
and injected intravenously (1 × 107 cells in 100 μL PBS) on day 14. Four hours later, 
spleen cells were obtained and green-fluorescent-positive cells were analyzed as 
remaining CFSE-labeled E.G7 cells by FACS. 
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3.3 Results and discussion 
3.3.1 Concentration-dependency of incorporation of BAM into cell membranes 
First, the concentration-dependency of incorporation of BAM derivatives into cell 
membranes was investigated. Living cells were treated with a biotinylated BAM at 
various concentrations and then stained with fluorescent-labeled streptavidin, followed 
with analysis by flow cytometry. As a result, the fluorescence derived from the 
incorporation of biotinylated BAM was adequately saturated above their concentrations 
of 20 μM (Figure 3-3). 
 
3.3.2 Concentration- and time-dependency of SrtA-mediated ligation on living cells 
Next, to investigate the concentration- and time-dependency of SrtA-mediated 
ligation reaction on living cells, a fluorescent-labeled substrate peptide was ligated with 
GGGYC-BAM on living cells at various concentrations for various times. A peptide 
including the substrate sequence, GYGLPETGG was purchased from Toray Research 
Center Inc. (Otsu, Japan) and modified with Alexa Fluor 488 (AF488) succinimidyl ester 
(from Invitrogen, Carlsbad, CA, USA) through an amide coupling reaction. The reaction 
mixtures including this AF488-labeled GYGLPETGG peptide (0-100 μM) and 6 μM SrtA 
were added onto the harvested living cells previously treated with GGGYC-BAM. After 
incubation for various time periods (0-3 h), these cells were rinsed and analyzed with a 
flow cytometer. As a result, at all concentrations of substrate peptides, the mean 
fluorescence of the cells treated for 2 h was almost the same as that for 3 h (Figure 3-4). 
From these results, the SrtA-mediated ligation reaction on living cells was confirmed to 
reach equilibrium in 2 h. 
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3.3.3 SrtA-mediated in situ ligation of EGFP-LPETG with GGGYC-BAM on living cells 
Subsequently, EGFP-LPETG was displayed on the surface of HeLa cells through the 
SrtA-mediated modification of BAM under optimal condition invested previously. Before 
the SrtA reaction, a conjugate of the GGGYC-BAM was incorporated into the cell 
membrane by simply dropping this solution onto the culture dish followed by incubation 
for 15 min. After removal of free GGGYC-BAM, both EGFP-LPETG and SrtA were added 
to the culture dish to perform the SrtA-mediated in situ ligation between EGFP-LPETG and 
the GGGYC-BAM. As shown in Figure 3-5A, the fluorescence of EGFP was clearly 
observed on the cell membrane after 2 h of the reaction and the removal of the free EGFP-
LPETG. Conversely, without SrtA, such EGFP fluorescence was not observed (Figure 3-5A). 
Furthermore, with SrtA, the EGFP fluorescence-positive ratio of living cells was 84%, 
whereas without SrtA, it was 1.2% (Figure 3-5B). Thus, EGFP was successfully displayed 
on living cells with high efficiency using the presented in situ method. 
 
3.3.4 Confirmation of the site-specificity of EGFP and BAM ligation 
To confirm the specific modification of EGFP with the GGGYC-BAM, the products 
of the SrtA-mediated reaction both in vitro and in situ were analyzed by SDS-PAGE and 
western blotting analysis. In the product of the in vitro reaction, a shifted green fluorescent 
band was detected above the band of intact EGFP-LPETG by fluorescent image analysis of 
the electrophoretic gel (Figure 3-6A, lane 6). In addition, this shifted band was not 
detected by western blotting analysis using an anti-hexahistidine tag antibody (Figure 
3-6B, lane 6). Here, a hexahistidine tag was fused at the end of C-terminus of EGFP-LPETG. 
Accordingly, these results strongly suggest that the shifted band was derived from the 
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BAM-modified EGFP, which bear a bulky PEG-lipid and lost the hexahistidine tag. 
Moreover, the same shifted band was detected from the lysate of the cells, in which the 
in situ SrtA-mediated modification was performed (Figure 3-6A, lane 10). Thus, by both 
in vitro and in situ modification, EGFP-LPETG was site-specifically modified with the 
GGGYC-BAM. 
 
3.3.5 Effects of incorporated site-specific Fc1-BAM and Fc2a-BAM conjugates on 
phagocytosis by dendritic cells 
LPETG-fused Fc domains of mouse IgG1 and IgG2a (Fc1-LPETG and Fc2a-LPETG) were 
displayed on E.G7 cells through in situ SrtA-mediated modification. As is the case with 
EGFP-LPETG, Fc1-LPETG and Fc2a-LPETG were successfully displayed on E.G7 cells, as 
confirmed by CLSM observation (Figure 3-7A) and FACS analysis after immunostaining 
(Figure 3-7B). These Fc domain-displayed E.G7 cells were co-cultured with immature 
DCs at 37°C. Figure 3-8 shows the phagocytosis rate of DCs under various conditions of 
treatment for E.G7 cells. Compared with no treatment or treatment with only the 
GGGYC-BAM, display of the Fc increased the phagocytosis rate, and especially, the 
phagocytosis rate was increased almost four-fold by displaying Fc2a-LPETG. On the other 
hand, display of Fc1-LPETG led to only a slight increase in the phagocytosis rate; although 
the mean amounts of displayed Fc domains per cell were almost the same in the FACS 
analysis (Figure 3-7B). Among the IgG subclasses, IgG2a are generally considered to be 
more active for immune effector responses than IgG1 [43]. This is because IgG1 strongly 
binds to both the activating and inhibitory FcγRs, whereas IgG2a binds with low affinity 
to the inhibitory FcγR. In FcγR-mediated phagocytosis, IgG1 cluster immune complex 
with the inhibitory FcγRIIb and dampen phosphorylated signals for initiating 
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phagocytosis via recruiting phosphatases on the immunoreceptor tyrosine-based 
inhibitory motifs (ITIM) of FcγRIIb [43, 44]. The present difference in the phagocytosis 
rates between Fc1-LPETG and Fc2a-LPETG is assumed to be derived from the properties of 
IgG1 and IgG2a, respectively.  
 
3.3.6 Comparison between random and site-specific BAM conjugates 
To compare the effect of random IgG-BAM conjugates and site-specific Fc-BAM 
conjugates, random IgG-BAM conjugate and site-specific Fc2a-BAM conjugate were 
displayed on E.G7 cells as described in Section 2.2.4 and Section 3.2.6, respectively. As 
expected, modification of site-specific Fc2a-BAM conjugate induced phagocytosis more 
effectively than random IgG-BAM conjugate (Figure 3-8). This result suggests that site-
specific ligation between Fc and BAM is an effective method to display Fc on ATCs 
without altering the interaction between FcγR on DCs. 
 
3.3.7 Anti-tumor effect of site-specific Fc-BAM conjugate on DC vaccination 
To investigate the anti-tumor effect of DC vaccine loaded with Fc domain-modified 
tumor cells, tumor cytotoxicity was evaluated. Mice were immunized twice with DCs 
phagocytizing E.G7 cells modified with Fc domains. Seven days after the second 
immunizations, CFSE-labeled E.G7 cells were injected intravenously. When the anti-
tumor cytotoxicity were induced, immune cells will kill E.G7 cells and CFSE positive 
cell ratio in spleen cells will decrease. As a result of FACS analysis, CFSE-labeled E.G7 
cell positive ratio was significantly decreased in spleen cells of the mice that were 
immunized with DCs pulsed with E.G7 cells displaying Fc2a-BAM (Figure 3-9). On the 
other hand, other mice that were immunized with DCs pulsed with Fc1-BAM treated 
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E.G7 or non-treated E.G7 showed slight deceases of CFSE-labeled E.G7 cells. This result 
indicates that DCs loaded with more ATCs induce stronger anti-tumor immunity. 
Furthermore, the efficiency of Fc domain-modified tumor cells as a source for a DC 
vaccine was evaluated in tumor-bearing mouse model. Mice were immunized twice with 
DCs treated with various conditions and seven days after the second immunizations, these 
mice were confronted with E.G7 cells, and the size of tumor on each mouse was observed. 
As a result, inhibition of tumor growth was confirmed on the mice that were immunized 
with DCs pulsed with E.G7 cells displaying Fc2a-BAM, whereas mice treated with DCs 
pulsed with E.G7 cells displaying Fc1-BAM showed no significant protection against 
tumor growth (Figure 3-10). Again, this result indicates that the more ATCs loaded to 
DCs, the stronger anti-tumor immunity is induced even in the body. Hence, site-specific 
Fc2a-BAM conjugate has a potential to improve clinical responses in DC vaccines. 
 
3.4 Conclusion 
In this chapter, to conjugate BAM on IgG without inhibiting Fc-FcγR interaction, I 
investigated a novel method to conjugate specific site of Fc domain and BAM via 
enzymatic reaction of SrtA. Since SrtA-mediated transpeptidation reactions is a facile 
detergent-free enzymatic reaction, SrtA reaction exhibit low protein denaturation and 
cytotoxicity compared to conventional site-specific lipidation methods which require the 
coexistence of amphiphilic reagents such as polar organic cosolvents and detergents that 
suppress aggregation of lipidated proteins in vitro. First, I used EGFP as a tool protein to 
optimize the condition of the reaction and I succeeded to display EGFP on living cells 
with high efficiency by SrtA-mediated in situ ligation method. I also confirmed the site-
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specific modification of EGFP and BAM by multiple method. Subsequently, I prepared 
LPETG-fused Fc domains of mouse IgG1 and IgG2a (Fc1-LPETG and Fc2a-LPETG). Among 
the subclasses of mouse IgG, IgG2a show stronger interaction than IgG1 with FcγRI on 
DCs which is an active receptor for phagocytosis. Therefore, comparison of functions 
between Fc1-BAM and Fc2a-BAM indicate the difference of reaction between FcγR on 
DCs. Both Fc domain were successfully displayed at the same amount on cancer cells 
without aggregation under an amphiphilic reagent-free condition. Compared with no 
treatment, the phagocytosis rate was increased almost four-fold by displaying Fc2a-BAM. 
On the other hand, display of Fc1-BAM led to only a slight increase in the phagocytosis 
rate. As described above, since the activation of phagocytosis of DCs via Fc-FcγR 
interaction differ by the subclass of IgG, it is estimated that Fc domains displayed on 
ATCs interacted functionally with FcγR on DCs and therefore, induced strong 
phagocytosis. In addition, compared to randomly conjugated IgG-BAM prepared by the 
method described in Chapter 2, site-specifically conjugated Fc2a-BAM induced 
phagocytosis of ATCs by DCs more effectively, which again indicates the functional 
interaction of Fc2a and FcγR. Finally, in vivo anti-tumor effect of vaccination of the DCs 
which phagocytized various IgG(Fc)-BAM conjugate treated ATC were evaluated. As 
expected, site-specific Fc-BAM treated ATCs induced stronger tumor immunity and 
delayed tumor development in mouse. Altogether, these result suggest that combination 
use of SrtA and BAM to modify Fc on tumor cells has a potential to improve clinical 
responses of DC immunotherapy. 
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Figure 3-1.  (A) Chemical structure of BAM used in chapter 3. (B) Schematic 
illustration of sortase A-catalyzed modification of a Fc domain of IgG with BAM 
presented on cell membranes. 
  
42 
 
 
 
Figure 3-2.  RP-HPLC chromatogram of a GGGYC peptide before and after reaction 
with maleimidyl BAM. The peak of peptide was detected by measuring the absorbance 
at 220 nm. Free GGGYC peptide was detected at 10.3 min. 
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Figure 3-3.  Incorporation of a biotinylated PEG-lipid onto living cells at various 
concentrations. The cells treated with biotinylated BAM for 15 min were stained with 
AF488-labeled streptavidin, followed with FACS analysis. 
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Figure 3-4.  SrtA-modified ligation of an AF488-labeled substrate peptide with a PEG-
lipid on living cells at various substrate concentrations for various time periods. 
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Figure 3-5.  Sortase A-catalyzed modification of enhanced green fluorescent protein 
with BAM in situ and in vitro. HeLa cells were treated with GGGYC-BAM and 
successively with EGFP-LPETG with or without SrtA on living cells (in situ) or in solution 
(in vitro). (A) The fluorescent images merged with the bright-field images were obtained 
with a confocal laser scanning microscope. The scale bar is 20 μm. (B) Qualitative 
analysis of the incorporation of EGFP into the membrane of HeLa cells by flow cytometry. 
The number described in each FACS histogram indicates the green fluorescence-positive 
ratio of living cells. 
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Figure 3-6.  Confirmation of sortase A-catalyzed modification of EGFP with BAM in 
vitro or in situ. EGFP-LPETG and GGGYC-BAM were incubated with or without SrtA in 
solution (in vitro) or on living cells (in situ). The reaction solution (in vitro) or cell lysate 
(in situ) were loaded on SDS-PAGE gel and analyzed by fluorescent scanning (A) or 
western blotting with an anti-His-tag antibody (B). 
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Figure 3-7.  Sortase A-catalyzed modification of the Fc domains of mouse IgG1 and 
IgG2a on E.G7 cells. (A) Fluorescent microscopic images of living E.G7 cells, modified 
with the Fc domains of mouse IgG1 (Fc1-BAM) and IgG2a (Fc2a-BAM). The Fc domains 
were stained with a fluorescent-labeled anti-Fc antibody. The scale bar is 20 μm. (B) 
FACS analysis of E.G7 cells modified with the Fc domains of mouse IgG1 (Fc1-BAM) 
and IgG2a (Fc2a-BAM). The fluorescent intensity of the E.G7 cells modified with the Fc 
domains and stained by the fluorescent-labeled anti-Fc antibody. The fluorescent intensity 
correlates with the amount of the Fc domains modified on E.G7 cells. Each data point 
represents the mean ± S.E. (n = 3). 
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Figure 3-8.  The phagocytosis rate of E.G7 cells treated with various combinations of 
the BAM, SrtA mediated site-specific Fc1-BAM and Fc2a-BAM conjugates, random 
IgG-BAM conjugates or tumor specific SF25 with DC. Each data point represents the 
mean ± S.E. (n = 3). *, *** p < 0.05, 0.001 vs non treated (student’s t-test). ##, ### p < 
0.01, 0.001 vs Fc2a-BAM (student’s t-test).  
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Figure 3-9.  Analysis of tumor cytotoxicity of mice immunized with DCs prepared 
under various conditions. Mice were vaccinated with either PBS (PBS), DCs (DC),  
apoptotic E.G7 cells (E.G7[-]), DCs pulsed with non-treated apoptotic E.G7 cells (DC 
(E.G7[-])), DCs pulsed with Fc1-displaying apoptotic E.G7 cells (DC (E.G7[Fc1-BAM])) 
and DCs pulsed with Fc2a-displaying apoptotic E.G7 cells (DC (E.G7[Fc2a-BAM])). 
E.G7 cells were fluorescently stained with CFSE and injected intravenously 14 days after 
first vaccination. Four hours later, spleen cells were obtained and green-fluorescent-
positive cells were analyzed as remaining CFSE-labeled E.G7 cells by FACS. Each data 
point represents the mean ± S.E. (n = 3). # p < 0.05 vs Non treated (student’s t-test). * p 
< 0.05 vs PBS (student’s t-test). 
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Figure 3-10.  Volumes of tumor after the transplantation of E.G7 cells in the mice 
immunized with DCs. Mice were vaccinated with either PBS (PBS), DCs (DC),  
apoptotic E.G7 cells (E.G7[-]), DCs pulsed with non-treated apoptotic E.G7 cells (DC 
(E.G7[-])), DCs pulsed with Fc1-displaying apoptotic E.G7 cells (DC (E.G7[Fc1-BAM])) 
or DCs pulsed with Fc2a-displaying apoptotic E.G7 cells (DC (E.G7[Fc2a-BAM])). E.G7 
cells were transplanted 14 days after first DC vaccination. Tumor volume was calculated 
using the formula: V = 0.5 x L x W2, where L is the longest diameter and W is the shortest 
diameter in mm. Mice were ethically sacrificed when the tumor volume exceeded 2,000 
mm3. Each data point represents the mean ± S.E. (n = 3). 
 
 
 
Chapter 4. General conclusion and perspectives
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4.1 General conclusion 
The main purpose of this study was to investigate the most efficient method to 
display arbitrary IgG on cancer cells with the application of BAM to improve the effect 
of DC immunotherapy.  
In chapter 2, I studied on random IgG-BAM conjugate which showed successful 
modification of arbitrary IgG on various cancer cells. Although this randomly conjugated 
IgG-BAM by using amine-coupling reaction method was very simple and fast to prepare, 
it was very difficult to adjust a suitable conjugation ratio of BAM per IgG not to inhibit 
the effective interaction between IgG and FcγR. Indeed, ATCs treated with random IgG-
BAM conjugates were more efficiently phagocytosed by DCs than untreated ATCs, 
however, the effect was only about two-fold compared to no treatment. Therefore, I 
hypothesized that by investigating the site-specific ligation of IgG and BAM, ATCs might 
be phagocytosed by DCs more efficiently.  
Subsequently, in chapter 3, to conjugate BAM on IgG without inhibiting Fc-FcγR 
interaction, I studied on site-specific IgG(Fc)-BAM conjugate via enzymatic reaction of 
SrtA. This method was unique at the point to operate the ligation of BAM and Fc fragment 
on the cell surface. This method successfully conjugated Fc and BAM site-specifically 
and enhanced DC phagocytosis of ATCs more efficiently than random IgG-BAM 
conjugate by displaying functional Fc to FcγR on DCs. Furthermore, vaccination of the 
DCs which phagocytized site-specific Fc-BAM treated ATCs induced strong in vivo anti-
tumor effect and delayed tumor development in mouse. These results strongly indicate 
that site-specific Fc-BAM treatment represents a promising method for opsonizing ATC 
with human arbitrary IgG(Fc), and that this approach will lead to objective clinical 
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responses in DC vaccines. Yet, there are lots of issues left to solve before clinical trial, 
such as, effect; is this method more efficient than conventional DC antigen loading 
method, side effect; is the carryover of SrtA, BAM and ATCs co-cultured with DCs safe 
to vaccinate. Further efforts will be required to approve site-specific Fc-BAM conjugate 
to clinical of DC immunotherapy. 
 
4.2 Perspectives 
In this study, the efficient method for displaying soluble proteins on living cells was 
successfully developed by employing both BAM and SrtA. The present in situ protein 
modification approach could fully resolve the conventional difficulties of protein 
lipidation caused by the aggregation-prone action of hydrophobic lipids. Recently, the 
similar lipidation approach with SrtA was reported as a protein modification on liposomes 
[45 ]. However, in this previously-reported work, a diglycine-modified PEG-lipid was 
mixed with the lipids in organic solvent for incorporating onto liposome, and the 
application of this method to living cells has not been reported yet. On the other hand, as 
mentioned in the review written by Dozier and Distefano, 2015 [46], present work is the 
first report demonstrating that SrtA-catalyzed in situ protein modification was achieved 
on living cells and is applicable to the modulation of a biological cell-to-cell interaction. 
Critical point of this achievement was the employment of a PEG-dioleyl derivative 
(BAM) as a biocompatible anchor for incorporating the substrate of SrtA onto the 
membranes of living cells. In addition, the high specificity of the SrtA-mediated reaction, 
which enables specific ligation under the coexistence of many other membrane proteins, 
was also necessary for the modification on cell surfaces.  
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Thus, the combined use of a BAM and SrtA represents a very effective and simple 
approach to display target proteins on living cells via exogenous transduction, particularly 
useful for difficult-to-transfect cells, and is a promising tool for regulating and reinforcing 
cell-cell interactions in cell and tissue engineering fields. 
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